Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia
Status:
Withdrawn
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of changing to DuoTrav® (Travoprost
0.004%/Timolol 0.5%) from prior prostaglandin analogue or beta-blocker monotherapy in Russian
glaucoma patients with open-angle glaucoma or ocular hypertension whose intraocular pressure
(IOP) is uncontrolled while on their current treatment.